CMS has released the ASP file for HCPCS effective January 1, 2023.
Major Changes for 2023:
CMS has increased payments for Biosimilar drugs to ASP of the biosimilar drug plus 8% of the ASP of the reference product.
- Most biosimilar reimbursements have dropped significantly from October to January indicating aggressive price competition among biosimilars.
- Reference drug reimbursement rates hold steady.
- January 2023 HCPCS codes and Payment limits are available NOW on BuyandBill.com
Biosimilar Reimbursement Trends October 2022 to January 2023